MONITORING AGENCY REPORT FOR THE QUARTER ENDED 30TH JUNE, 2025 FOR FUNDS RAISED THROUGH PREFERENTIAL ISSUE
INDSWFTLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Ind-Swift Laboratories has submitted the CARE Ratings monitoring agency report for the quarter ended June 30, 2025, covering its Rs. 314.60 crore preferential issue of 2.60 crore fully convertible warrants (allotted August 30, 2024). Of this, only Rs. 115.03 crore has been raised so far, with Rs. 92.61 crore utilised and Rs. 22.42 crore sitting idle in a Bank of India warrants receipt account. During Q1FY26, the company used Rs. 14.37 crore for business expansion and Rs. 1.50 crore for working capital, while no funds went toward subsidiary investments or general corporate purposes in the quarter. The monitoring agency flagged that funds were transferred from the monitoring account to current accounts, causing commingling that limited its ability to independently verify end-use, though the company and its CA confirmed usage as per the offer document.
Shareholders should note that the stock price (Rs. 103.60 on August 11, 2025) is below the warrant exercise price of Rs. 121.00, raising the risk that warrant holders may skip conversion, which could derail the company's expansion funding plan. Additionally, the recent merger of group company Ind-Swift Limited effective August 8, 2025, and the prior sale of the API/CRAMS business mean the company is essentially a restructured entity moving into finished dosages, so investors should weigh the slow fund deployment and regulatory disclosures carefully.